Trial ID or NCT#

NCT01121640

Status

not recruiting iconNOT RECRUITING

Purpose

The Novel Markers Trial will compare the safety, feasibility and effectiveness of two different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either a first or second line screen. This study is the next step in a larger research effort to develop a blood test that can be used as a screening method for the early detection of epithelial ovarian cancer.

Official Title

A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

Eligibility Criteria

Ages Eligible for Study: 25 Years to 80 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No

Investigator(s)

Paula Hillard
Paula Hillard
Pediatric/adolescent gynecologist
Professor of Obstetrics and Gynecology (General Gynecology), Emerita
Allison W. Kurian, M.D., M.Sc.
Allison W. Kurian, M.D., M.Sc.
Medical oncologist, Breast specialist, Cancer geneticist
Professor of Medicine (Oncology) and of Epidemiology and Population Health

Contact us to find out if this trial is right for you.

CONTACT

Ashley Powell
(650) 724-3308